Larimar Therapeutics, Inc. (LRMR) is a clinical-stage biophysics company dedicated to developing innovative treatments for complex rare diseases. The company's primary focus is on Friedreich's ataxia, a debilitating, life-shortening and degenerative neuromuscular disorder. This is part of Larimar's broader commitment to delivering breakthrough therapies for patients suffering from rare genetic diseases for whom there are not adequately efficacious treatments.
Founded and formerly known as Zafgen, Inc., the company changed its name to Larimar Therapeutics, Inc. in 2020. The change was a part of the strategy to reposition the company towards the development of genetic disease treatments, achieving transformative outcomes. The name Larimar was chosen for its uniqueness and as a tribute to the rare blue Larimar stone found only in the Dominican Republic. The company's choice to name itself after the Larimar stone reinforces its commitment to finding unique, high-value solutions for rare diseases.
The leading therapeutic candidate in Larimar’s pipeline is CTI-1601, designed for the treatment of Friedreich's ataxia. Friedreich's ataxia is caused by a defect in the body's production of frataxin, an essential mitochondrial protein. CTI-1601 works by delivering frataxin protein to mitochondria, which helps restore critical functions and addresses the underlying frataxin deficiency in Friedreich's ataxia patients.
The company is diligently advancing CTI-1601 through its pivotal clinical trials. The FDA has granted it Orphan Drug, Fast Track, and Rare Pediatric Disease designations, reflecting the unique nature of the treatment and the critical need it meets. If successful, CTI-1601 could potentially mark a major milestone in treating Friedreich's ataxia and may significantly improve patients' quality of life.
Besides developing CTI-1601, Larimar is also studying other genetic diseases with the aim to expand its impressive portfolio. The company's approach exemplifies the very essence of precision medicine, which presents great potential for treating some of the most complex and devastating rare diseases.
Based in Pennsylvania, the company collaborates with leading researchers and healthcare professionals, continually seeking to advance knowledge in genetic diseases and improve therapeutic options. From the leadership team, comprised of biotechnology and rare disease experts, to its focused patient-centric approach, Larimar Therapeutics is poised to make a significant impact on the rare genetic disease treatment landscape.
In summary, Larimar Therapeutics is a pioneering and purpose-driven company, dedicated to transforming the lives of patients with rare genetic diseases. Its innovative research and commitment to developing breakthrough therapies could potentially change the course of treatment for many rare genetic diseases, bringing new hope to countless patients and their families.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Hennion & Walsh Asset Management Inc. has acquired a new position in Larimar Therapeutics, Inc. (NASDAQ:LRMR), purchasing 396,726 shares valued at approximately $1.21 million. This makes them a 0.38% owner of the company, with institutional investors collectively holding 91.92% of the stock. Insider activity also includes Director Thomas Edward Hamilton's purchase of 50,000 shares, increasing his holdings by 7.52%.
Dimensional Fund Advisors LP significantly increased its stake in Larimar Therapeutics (NASDAQ:LRMR) by 143.8% in the first quarter, acquiring an additional 470,968 shares to own a total of 798,462 shares valued at approximately $3.6 million. Institutional investors now hold 91.92% of the company's stock. Larimar Therapeutics, a clinical-stage biotechnology company developing a treatment for Friedreich’s ataxia, has a consensus "Buy" rating and a target price of $12.57 from analysts, despite some recent target reductions.
Renaissance Technologies LLC significantly increased its stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR) by 148.9% in the first quarter, now holding 739,942 shares valued at approximately $3.33 million. Institutional investors and hedge funds collectively own 91.92% of LRMR. Insider buying also occurred, with Director Thomas Edward Hamilton purchasing 50,000 shares, while analysts generally maintain a "Buy" rating with an average price target of $12.57.
Larimar Therapeutics (NASDAQ:LRMR) has received a consensus "Buy" rating from eleven analysts, with an average 12-month price target of $12.57, significantly higher than its current $4.10 price. Institutional investors own 91.92% of the company, and a director recently purchased 50,000 shares. The clinical-stage biotech company is developing CTI-1601 for Friedreich's ataxia and reported a smaller-than-expected quarterly loss of $0.30 per share.
Larimar Therapeutics (LRMR) faces substantial regulatory and manufacturing risks regarding its nomlabofusp drug, impacting its accelerated approval timeline. Delays in BLA submission or issues with third-party manufacturers could postpone commercialization and affect investor confidence. Despite these challenges, Wall Street analysts maintain a Strong Buy consensus rating for LRMR stock.
Larimar Therapeutics (LRMR) faces significant regulatory and manufacturing risks for its nomlabofusp drug, impacting its accelerated approval path. Delays in BLA submission or issues with third-party manufacturers, especially those with FDA Form 483 observations, could postpone commercialization and affect investor confidence. Despite these challenges, Wall Street maintains a "Strong Buy" consensus rating on LRMR stock.
SummitTX Capital L.P. has acquired a new stake of 379,765 shares in Larimar Therapeutics, Inc. (NASDAQ:LRMR) valued at approximately $1.71 million. This investment comes as other institutional investors have also adjusted their holdings in the company, which has 91.92% institutional ownership. Analyst sentiment for Larimar Therapeutics is largely positive, with a consensus "Buy" rating and a target price of $12.71, despite the stock trading near its 52-week low-to-mid range.